Neurol India Home 

Year : 2022  |  Volume : 70  |  Issue : 2  |  Page : 652--659

Cerebral Venous Thrombosis in COVID-19

Rajesh Benny1, Rakeshsingh K Singh1, Anil Venkitachalam2, Rakesh S Lalla3, Amit M Shah4, Vyankatesh Bolegave5, Ashutosh N Shetty4, Keyur C Panchal6, Jitendra Choudhary1, Anita Mathew1, Manoj Hunnur7, Kishore V Shetty7 
1 Department of Neurology, Fortis Hospital, Mulund, Maharashtra, India
2 Department of Neurology, Somaiya Superspeciality Centre, Mumbai, Maharashtra, India
3 Department of Neurology, Medihope Hospital, Kalyan, Maharashtra, India
4 Department of Neurology, Criticare Hospital and Research Centre, Mumbai, Maharashtra, India
5 Department of Neurology, Highland Superspeciality Hospital, Thane, Maharashtra, India
6 Department of Neurology, Sanjeevani Hospital, Mumbai, Maharashtra, India
7 Department of Neurology, Karuna Hospital, Mumbai, Maharashtra, India

Correspondence Address:
Dr. Rajesh Benny
1403, Tower 6, Runwal Greens, Mulund Goregaon Link Road, Bhandup (W), Mumbai - 400 078, Maharashtra

Background: COVID-19 causes a hypercoagulable state leading to thrombosis. Many of these thrombotic complications occur in those with severe disease and late in the disease course. COVID-19 has recently been associated with cerebral venous thrombosis (CVT). Objective: To study the onset of CVT in relation to COVID-19 and compare their characteristics and outcomes with non-COVID CVT patients admitted during the same period. Materials and Methods: This multicentric, retrospective study conducted between April 4 and October 15, 2020, included adult patients with CVT who were positive for the SARS-CoV-2 virus and compared them with CVT patients who were negative for the SARS-CoV-2 virus hospitalized during the same period. We studied their clinical profile, risk factors for CVT, and markers of COVID coagulopathy, imaging characteristics, and factors influencing their outcomes. Results: We included 18 COVID-19-infected patients and compared them with 43 non-COVID-19 CVT patients. Fourteen patients in the COVID-19 group presented with CVT without the other typical features of COVID-19. Thirteen patients had non-severe COVID-19 disease. Twelve patients had a good outcome (mRS ≤2). Mortality and disability outcomes were not significantly different between the two groups. Conclusion: Our study suggests a possible association between COVID-19 and CVT. CVT can be the presenting manifestation of an underlying COVID-19, occurring early in the course of COVID-19 and even in those with mild disease. Patients with worse GCS on admission, abnormal HRCT chest, severe COVID-19, and need for invasive ventilation had a poor outcome.

How to cite this article:
Benny R, Singh RK, Venkitachalam A, Lalla RS, Shah AM, Bolegave V, Shetty AN, Panchal KC, Choudhary J, Mathew A, Hunnur M, Shetty KV. Cerebral Venous Thrombosis in COVID-19.Neurol India 2022;70:652-659

How to cite this URL:
Benny R, Singh RK, Venkitachalam A, Lalla RS, Shah AM, Bolegave V, Shetty AN, Panchal KC, Choudhary J, Mathew A, Hunnur M, Shetty KV. Cerebral Venous Thrombosis in COVID-19. Neurol India [serial online] 2022 [cited 2022 Aug 10 ];70:652-659
Available from:;year=2022;volume=70;issue=2;spage=652;epage=659;aulast=Benny;type=0